CERo Therapeutics Holdings, Inc.
CERO
$5.40
-$0.10-1.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -121.23% | -122.02% | 153.11% | -183.07% | -17.02% |
| Total Depreciation and Amortization | -8.73% | -6.49% | -0.07% | 5.65% | 5.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 145.47% | 121.32% | -2,593.39% | 264.47% | -775.55% |
| Change in Net Operating Assets | -163.11% | 92.22% | 1,051.96% | 2,082.82% | 1,724.79% |
| Cash from Operations | -30.70% | 12.49% | -60.29% | -109.25% | -70.53% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -348.30% | -266.26% | -- |
| Issuance of Common Stock | -- | -0.77% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 5,023.90% | -6,281.21% | 133.25% |
| Cash from Financing | 5.06% | -11.68% | -- | -- | 357.41% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -100.92% | -9.68% | 94.47% | 79.76% | 37.25% |